Secretory Leukocyte Protease Inhibitor (SLPI)

SLPI is a 11.7kD cationic inhibitor of neutrophil elastase and to a lesser extent of cathepsin G. It is locally produced by epithelial cells in the lung, skin and other organs and by Polymorphonuclear leukocytes (PMN) and (in mice) by macrophages. In addition to its proteinase inhibitory properties that may serve to protect against proteolytic injury, it was recently shown that SLPI also displays several other functions such as antimicrobial and anti-inflammatory activities. These appear to be independent of its ability to inhibit PMN serine proteinases. SLPI has also been demonstrated to display antibacterial and antifungal activity at concentrations in which SLPI is present in mucosal secretions including those of the lung. Another possible role for SLPI is inhibition of protein-disulfide isomerase that is considered essential for invasion of a cell by the Human Immunodeficiency Virus (HIV).\n\nApplications:\nSuitable for use in Immunohistochemistry, Western Blot, Immunoprecipitation and ELISA. Other applications not tested.\n\nRecommended Dilution:\nImmunohistochemistry (Frozen/paraffin): 1:50 (5ug/ml) Paraffin sections were deparifinized, rehydrated and blocked woith normal serum. Specifin was fixed in 4% formalin for 4 hours. Optimal antigen retrieval with citrate buffer. \nWestern Blot: 1:50\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

S0635-03

Size

100ug

Applications

ELISA, IHC, IP, WB

Hosts

Mouse

Reactivities

Hum

Form

Supplied as a liquid in PBS, 0.02% sodium azide, 0.1% BSA.

P Type

Mab

Purity

Purified by Protein G affinity chromatography.

Isotype

IgG1

References

1. Wingens, M et al; Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J Invest Dermatol 1998, 111: 996 2. Nakao, R et al; Assessment of oral transmission using cell-free human immunodeficiency virus-1 in mice reconstituted with human peripheral blood leucocyte. Immunology 2003, 109: 271 3. Aarbiou, J et al. Human neuthrophil defensins and secrtory leukocyte proteinase inhibitor in squamous metaplastic epithelium of bronchial airways. Inflamm. Res 2004, 53:230-238 4. Tjabringa, S et al. Host defense effecotr molecules in mucosal secretions. FEMS immunol and med microbial 2005, 45:151 5. Bingle,L et al. WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Resp Res 2006, 7:61 6. Cheng, W et al; Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int J Cancer 2008, 123: 1787 7. Subramaniyam, D et al; Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis. Respirology 2011, 16: 300

Additional Info

Recognizes human secretory leukocyte proteinase inhibitor (SLPI; also known as antileukoprotease or ALP).